Johnson & Johnson (NYSE: JNJ) Sees New Price Target and FDA Approval Boost

Core Insights - Johnson & Johnson (JNJ) is focusing on expanding its pharmaceutical portfolio through potential acquisition opportunities, specifically Protagonist Therapeutics [2][6] - The company is set to report strong third-quarter earnings, with expected earnings of $2.76 per share and revenue of $23.76 billion, indicating growth from the previous year [3][6] - The FDA has approved JNJ's Simponi for children with ulcerative colitis, which has positively impacted the stock price and reflects the company's commitment to addressing unmet medical needs [4][6] Stock Performance - As of the latest trading, JNJ is priced at $191.29, showing a slight increase of 0.21, with a market capitalization of approximately $460.69 billion [5] - The stock has experienced fluctuations between a low of $190.31 and a high of $192.06 on the trading day, with a yearly high of $192.1 and a low of $140.68 [5] Analyst Insights - RBC Capital has set a new price target for JNJ at $209, suggesting a potential increase of approximately 9.26% from the current trading price [1][6]